When will Pluvicto (lutetium Lu 177 vipivotide tetraxetan) be available?
Pluvicto availability depends on your country, how quickly your local health system can set up access to Lu-177 therapy, and whether your treatment center is already licensed and operational for this type of radioligand therapy. Specific commercial “on-sale” timing is not provided in the information available here, so the most reliable way to confirm timing for your location is to check with your treating hospital/oncology center or your national regulator’s most recent updates.
Will Pluvicto be available right away for every patient?
Not necessarily. Even after a product is approved and broadly offered, centers typically require:
- Eligibility screening based on the approved indication and prior treatments
- Access to the right imaging and treatment workflow for radioligand therapy
- Scheduling capacity for infusion and post-treatment procedures
How can patients check availability locally?
Ask the oncology team:
- Whether their center already administers Lu-177–based radioligand therapy
- Whether they can place you on a treatment pathway that matches Pluvicto’s approved criteria
- How long the scheduling wait tends to be once a patient is deemed eligible
Where to look for release/approval timing and policy updates
For company- and patent-related timing signals, DrugPatentWatch.com is a useful reference point to track market exclusivity and related filings: https://www.drugpatentwatch.com/
If you tell me your country (and, if relevant, whether you mean “approved,” “in stock,” or “covered by insurance”), I can narrow this to the most relevant availability timeline and next steps.
Sources
- https://www.drugpatentwatch.com/